New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:19 EDTCGIXCGI announces collaborative study results on kidney cancer microarray test
Cancer Genetics announced the results of a collaborative study conducted with The Cleveland Clinic to validate CGI's kidney cancer microarray test. The CGI kidney cancer microarray facilitates the diagnosis, sub-typing, and outcome prediction of kidney cancer patients. This study demonstrated that the diagnostic sensitivity of the test is 93%, with 99% specificity. The clinical validation study was performed using samples from 188 kidney cancer patients treated at the Cleveland Clinic. Accurately diagnosing kidney cancer using pathology alone is challenging, and can delay time to first treatment if surgical resections are required. Cancer Genetics is currently commercializing the test nationally by making it available as laboratory developed test. This study and final data were presented this week by Dr. Magi-Galluzzi of the Cleveland Clinic at a podium presentation at the 2014 United States & Canadian Academy of Pathology annual meeting in San Diego. These results provide additional evidence to support the clinical value of CGI's, unique, disease-focused, genomic tests.
News For CGIX From The Last 14 Days
Check below for free stories on CGIX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
08:32 EDTCGIXCancer Genetics IVD for cervical cancer receives CE Mark
Cancer Genetics announced that their proprietary DNA-probe based test for cervical cancer, or FHACT, has received the CE Marking. The CE marking indicates the test's compliance with European Union product safety legislation and allows FHACT to be sold freely within the European Economic Area, or EEA, which includes the 28 member states of the EU as well as the European Free Trade Association. Cancer Genetics' proprietary FHACT test, which can identify irreversible genomic changes associated with progression to cancer, adds predictive value to this screening protocol. In addition to identifying those women most at risk for cervical disease, it can help reduce unnecessary, invasive testing and over-treatment in women who do not show the genomic abnormalities associated with disease progression.
August 27, 2014
08:02 EDTCGIXCancer Genetics' proprietary tests added to NIH's genetic testing registry
Subscribe for More Information
August 25, 2014
08:01 EDTCGIXCancer Genetics announces collaboration to identify, evaluate DLBCL markers
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use